Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in IntangiblesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Astrazeneca (AZNCF) over the last 15 years, with Q4 2025 value amounting to $4.3 billion.

  • Astrazeneca's Free Cash Flow fell 752.43% to $4.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $21.5 billion, marking a year-over-year increase of 2071.94%. This contributed to the annual value of $21.5 billion for FY2025, which is 2071.94% up from last year.
  • According to the latest figures from Q4 2025, Astrazeneca's Free Cash Flow is $4.3 billion, which was down 752.43% from $6.9 billion recorded in Q3 2025.
  • In the past 5 years, Astrazeneca's Free Cash Flow ranged from a high of $6.9 billion in Q3 2025 and a low of $303.0 million during Q4 2021
  • Over the past 5 years, Astrazeneca's median Free Cash Flow value was $3.9 billion (recorded in 2022), while the average stood at $3.7 billion.
  • Its Free Cash Flow has fluctuated over the past 5 years, first skyrocketed by 17219.96% in 2021, then plummeted by 752.43% in 2025.
  • Quarter analysis of 5 years shows Astrazeneca's Free Cash Flow stood at $303.0 million in 2021, then soared by 715.51% to $2.5 billion in 2022, then increased by 23.43% to $3.1 billion in 2023, then skyrocketed by 51.64% to $4.6 billion in 2024, then decreased by 7.52% to $4.3 billion in 2025.
  • Its Free Cash Flow was $4.3 billion in Q4 2025, compared to $6.9 billion in Q3 2025 and $5.4 billion in Q2 2025.